Charlottesville, VA – May 10, 2016– HemoSonics today announced that a paper comparing its novel SEER technology to Thromboelastography (TEG) was published online in Anesthesia and Analgesia. The paper, A Comparison of a New Ultrasound-based Whole Blood Viscoelastic Test (SEER Sonorheometry) versus Thromboelastography (TEG) in Cardiac Surgery, describes the results of a study conducted at Virginia Commonwealth University in 50 cardiac surgery patients. The study compared the results of a research version of the Quantra™, a point-of-care in vitro diagnostic platform that measures blood clot formation and breakdown and provides actionable information to aid in the management of critical bleeding and clotting, with the TEG 5000 and standard laboratory tests.
The study found that the Quantra results were significantly correlated with TEG measures of clot time (r=0.6-0.7) and clot stiffness (r=0.8-0.9) as well as standard laboratory tests for fibrinogen and platelet count (r=0.6-0.8). Complete Quantra results were available substantially faster than the TEG results (11 minutes vs 42 minutes, averages of Quantra vs TEG respectively), an important distinction in critical care settings where rapid treatment of bleeding is of the essence.
The study substantiated the use of the Quantra’s Fibrinogen Contribution parameter, suggesting it may determine a more functional fibrinogen activity as compared to the TEG and conventional laboratory methods. In addition, the study showed a significant correlation between platelet count and the Quantra’s Platelet Contribution measure of platelet function (r=0.6-0.8), a parameter existing viscoelastic technologies do not measure.
“Current viscoelastic testing is limited by long result times and incomplete parameter measures,” said Dr. Bruce Spiess, Professor and Associate Chief Anesthesiology (Research) at University of Florida and lead author of the paper. “These results show the Quantra provides comparable clot time and clot stiffness results to existing technologies, and additional rapid information in its Fibrinogen Contribution and Platelet Contribution measures that are not currently available. The Quantra has the potential to be a major leap forward in viscoelastic testing.”
“The results of this study provide a first important demonstration of the Quantra and highlight its potential utility in the fast-paced critical care setting,” said Dr. Francesco Viola, Chief Science Officer of HemoSonics. “Clinicians are adamant that they need fast, comprehensive results to provide optimal treatment. The Quantra is a potential tool for providing this information.”
Reynolds PS, Middleton P, McCarthy H, Spiess BD. A Comparison of a New Ultrasound-based Whole Blood Viscoelastic Test (SEER Sonorheometry) versus Thromboelastography (TEG) in Cardiac Surgery. Anesth Analg. 2016; doi:10.1213/ANE.0000000000001362.